WALTHAM, Mass.--(BUSINESS WIRE)--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today reported that its lead product candidate, ZYBRESTATTM (combretastatin A4 phosphate / CA4P), demonstrated anti-leukemic effects in preclinical studies published online and ahead of print on November 16, 2007 on the website of the journal BLOOD.
